AbbVie news in 2026: 34 dated events
The latest AbbVie event on this page is dated Nov 12, 2026. prnewswire.com reported: Lymphoma Research Foundation to Honor Leaders in Research, Patient Advocacy and Philanthropy at 2026 Annual Gala.
Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn
Get AbbVie's live signals in Claude or ChatGPT, or by API
What changed at AbbVie this week? Use Autobound signals for abbvie.com.- Dated events
- 34
- Last 90 days
- 28
- Latest
- Nov 12, 2026
Source: Autobound Signal API · 112 signals tracked for AbbVie · updated
News · latest 10
Latest AbbVie news
Showing 10 of 34 dated events. The Signal API returns all of them.
Get them with one API call- Lymphoma Research Foundation to Honor Leaders in Research, Patient Advocacy and Philanthropy at 2026 Annual GalaAbbVie will receive the Corporate Leadership Award from the Lymphoma Research Foundation at its 2026 Annual Gala.
- PsiThera Closes $25 Million Financing to Advance Oral Therapeutics in ImmunologyAbbVie Ventures participated as a new investor in PsiThera's $25 million financing round, with Managing Director Claire Leurent joining PsiThera's Board of Directors.
- AbbVie expands Oxford R&D facility as part of £120 million-plus investmentAbbVie expanded its UK research and development facility in Oxford as part of an investment of more than £120 million.
- AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82AbbVie reported third-quarter 2026 revenue of $17.404 billion, an increase of 10.3% year over year.
- AbbVie Reports Third-Quarter 2026 Financial ResultsWith Apogee Therapeutics
- AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple MyelomaAbbVie submitted a Biologics License Application to the FDA for its multiple myeloma drug candidate etentamig.
- U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseaseAbbVie announced that the U.S. FDA approved a subcutaneous induction regimen for SKYRIZI for adults with moderately to severely active Crohn's disease.
- AbbVie unveils positive Phase III results for lutikizumabAbbVie published positive Phase III results evaluating the efficacy and safety of its investigational drug lutikizumab.
- AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO ReadoutsAbbVie reported Phase 2a trial data for its investigational dual-targeting Crohn's disease therapy ABBV-466.
- AbbVie's subcutaneous risankizumab meets Phase III AFFIRM endpointsAbbVie reported Phase III trial results for its subcutaneous induction regimen of risankizumab (Skyrizi) in patients with Crohn's disease.
Showing 10 of 34 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track AbbVie with the Signal API
One POST /v1/companies/enrich call with abbvie.com returns AbbVie news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","signal_types":["news"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.
Same industry
News at related companies
Questions about AbbVie news
What is the latest news on AbbVie?
What is going on with AbbVie?
Page updated , the date of the newest row on this page.
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .